Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04608318
Title Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) (CLL17)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors German CLL Study Group
Indications
Therapies
Age Groups: adult | senior
Covered Countries NLD | ITA | ESP | DEU | BEL | AUT


No variant requirements are available.